During the extended duration of treatment, two patients experienced a deterioration in their conditions of schizophrenia and depression; however, the overall results showed that patients’ psychiatric conditions remained stable during treatment with VMAT2 inhibitors. Here, SLC18A2 is linked to depressive symptom measurement.